Lipfendra is a new daily cholesterol pill made by Merck.

How does Lipfendra work?

Lipfendra works by blocking a protein called PCSK9, which helps the liver remove bad cholesterol from the bloodstream.

PCSK9 is a protein that works in the liver, preventing the recycling of LDL receptors, which increases bad cholesterol.

● Importantworld10 outlets covering this

FDA approves new cholesterol-lowering pill, doctor explains what it does differently

First publishedJul 16, 11:46 UTC

Last updatedJul 17, 11:41 UTC · 13m ago

121111111

10 outlets over time — hover a bar for its window & outletslast updated

FDA approves new cholesterol-lowering pill, doctor explains what it does differently - image 1 — 1 / 7

FDA approves new cholesterol-lowering pill, doctor explains what it does differently - image 2 — 1 / 7

● Story signals

How strong is this topic?

8.6/10Significanceimpact & urgency

7.0/10Source trustoutlet authority

10Outletsindependent sources

Significance weighs impact, urgency & coverage breadth · Source trust is the outlets' average authority · more outlets means a more confirmed story.

Answer

The FDA approved a new daily cholesterol pill called Lipfendra, made by Merck, which works differently from popular statins.

Reported by 10 outlets — NPR Health, CBS News, The Guardian US, NBC News, The Hill, and 4 more. See all sources ↓

The FDA approved a new pill to lower cholesterol. This pill is called Lipfendra and is made by Merck. It works differently from popular statins.

Why it matters

This new pill may help people with high cholesterol levels who have not seen results with statins. It is a new treatment option for millions of Americans.

In brief

What is Lipfendra?: Lipfendra is a new daily cholesterol pill made by Merck.
How does Lipfendra work?: Lipfendra works by blocking a protein called PCSK9, which helps the liver remove bad cholesterol from the bloodstream.
What is PCSK9?: PCSK9 is a protein that works in the liver, preventing the recycling of LDL receptors, which increases bad cholesterol.

Different angles across outlets

Coverage map

How outlets are framing the same story

These are the main editorial angles found across reporting. Use them to quickly compare what different outlets emphasize, omit, or question.

The outlets report the FDA approval of Lipfendra in a straightforward manner, focusing on its benefits and how it works. Some outlets provide more details about the pill's mechanism of action and its potential impact on patients.

Coverage cardFraming signal
1Angle
Scouting report
Lipfendra is a new treatment option for people with high cholesterol levels.
Sources3
TypeAngle
CBS NewsJul 17, 00:42emphasizes the pill's potential benefits
NBC NewsJul 16, 12:59explains how the pill works
The Guardian USJul 16, 15:28highlights the pill's alternative to statins
Coverage cardFraming signal
2Angle
Scouting report
Lipfendra is a powerful new cholesterol-lowering drug.
Sources3
TypeAngle
NPR HealthJul 17, 08:42emphasizes the pill's potency
CNBC Top NewsJul 16, 11:46reports on the FDA approval
Fox News LatestJul 16, 13:35highlights the pill's effectiveness
Coverage cardFraming signal
3Angle
Scouting report
Lipfendra is a costly but powerful new cholesterol-busting pill.
Sources1
TypeAngle
Chicago Sun-TimesJul 16, 16:30emphasizes the pill's high price
Coverage cardFraming signal
4Angle
Scouting report
Lipfendra is a first-of-its-kind pill to drastically reduce cholesterol.
Sources2
TypeAngle
The HillJul 16, 18:56highlights the pill's innovative approach
Seattle TimesJul 16, 17:49reports on the pill's approval and benefits

Related in the knowledge graph

organizationCBS Evening News organizationCenter organizationColumbia University's Irving Medical organizationDr. Corey Bradley organizationFDA

Sources (10)

Avg source rating 7.0/10

Processing cluster

A1A2A3B1B2B3

Share this article

X / Twitter LinkedIn WhatsApp

Summarize with AI (opens AI chat with article URL · Gemini: prompt copied to clipboard)

GPT Perplexity Gemini Claude